Drug firm Glenmark Pharmaceuticals on Saturday said it has launched antiviral drug Favipiravir, under the brand name Fabiflu , or the treatment of patients with mild to moderate Covid-19 at a price of about Rs 103 per tablet.
The drug will be available as a 200 mg tablet at a maximum retail price (MRP) of Rs 3,500 for a strip of 34 tablets, Glenmark Pharmaceuticals said.
Fabiflu is the first oral favipiravir-approved medication in India for the treatment of Cod-19, it said in a statement.
It is a prescription-based medication, with recommended dose being 1,800 mg twice daily on day one, followed by 800 mg twice daily up to day 14, it added.
The Mumbai-based firm had on Friday received the manufacturing and marketing approval from the Drugs Controller General of India (DCGI).
"This approval comes at a time when cases in India are spiralling like never before , putting a tremendous pressure on our healthcare system" , Glenmark Pharmaceuticals chairman and managing director Glenn Saldanha said in the statement .
The company has successfully develop the Active Pharmaceutical Ingredient (API) and the formulation for Fabiflu through its in-house research and development team, Glenmark said.
Favipiravir can be used for coronavirus patients with co-morbid conditions such as diabetes and heart disease with mild to moderate Covid-19 symptoms, Glenmark said.
It offers rapid reduction in viral load within four days and provides faster symptomic andradiological improvement.
Favipiravir has shown clinical improvement of upto 88 percent in mild to moderate covid-19 cases, it said .
Favipiravir has been approved in Japan since 2014 for the treatment of novel or re-emerging influenza virus infections.
India on Saturday saw another record spike of 14,516 new Covid-19 cases in a single day, pushing the tally to 3,95,048, while the death toll rose to 12,948 with 375 new fatalities, according to Union health ministry data.
The drug will be available as a 200 mg tablet at a maximum retail price (MRP) of Rs 3,500 for a strip of 34 tablets, Glenmark Pharmaceuticals said.
Fabiflu is the first oral favipiravir-approved medication in India for the treatment of Cod-19, it said in a statement.
It is a prescription-based medication, with recommended dose being 1,800 mg twice daily on day one, followed by 800 mg twice daily up to day 14, it added.
The Mumbai-based firm had on Friday received the manufacturing and marketing approval from the Drugs Controller General of India (DCGI).
"This approval comes at a time when cases in India are spiralling like never before , putting a tremendous pressure on our healthcare system" , Glenmark Pharmaceuticals chairman and managing director Glenn Saldanha said in the statement .
The company has successfully develop the Active Pharmaceutical Ingredient (API) and the formulation for Fabiflu through its in-house research and development team, Glenmark said.
Favipiravir can be used for coronavirus patients with co-morbid conditions such as diabetes and heart disease with mild to moderate Covid-19 symptoms, Glenmark said.
It offers rapid reduction in viral load within four days and provides faster symptomic andradiological improvement.
Favipiravir has shown clinical improvement of upto 88 percent in mild to moderate covid-19 cases, it said .
Favipiravir has been approved in Japan since 2014 for the treatment of novel or re-emerging influenza virus infections.
India on Saturday saw another record spike of 14,516 new Covid-19 cases in a single day, pushing the tally to 3,95,048, while the death toll rose to 12,948 with 375 new fatalities, according to Union health ministry data.
0 Comments